- Home
- UPXI vs SCLX Comparison
UPXI vs SCLX Comparison
Compare UPXI & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | SCLX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 55.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UPXI | SCLX |
|---|---|---|
| Price | $0.79 | $6.34 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 921.7K | 65.4K |
| Earning Date | 05-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.49 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,811,345.00 | ★ $30,253,000.00 |
| Revenue This Year | $118.99 | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $4.20 |
| 52 Week High | $9.12 | $34.27 |
Technical Indicators
Market Signals| Indicator | UPXI | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 38.14 |
| Support Level | $0.75 | $6.23 |
| Resistance Level | $0.89 | $7.77 |
| Average True Range (ATR) | 0.05 | 0.41 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 53.39 | 32.64 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.